About: Interferon-α2b and ribavirin treatment improves outcome in MERS-CoV-infected rhesus macaques

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Interferon-α2b and ribavirin treatment improves outcome in MERS-CoV-infected rhesus macaques Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Interferon-α2b and ribavirin treatment improves outcome in MERS-CoV-infected rhesus macaques
Creator	Munster, Vincent Falzarano, Darryl Feldmann, Heinz Feldmann, Friederike Bushmaker, Trenton Martellaro, Cynthia Okumura, Atsushi Scott, Dana Baseler, Laura Benecke, Arndt De Wit, Emmie Brining, Doug Katze, Michael Rasmussen, Angela
Source	Medline; PMC
abstract	The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) is of global concern – causing severe respiratory illness with 97 confirmed cases and 46 deaths(1). Therapeutic interventions have not been evaluated in vivo, thus patient management relies exclusively on supportive care, which given the high case-fatality rate is not highly effective. The rhesus macaque is the only known disease model for MERS-CoV, developing an acute localized-to-widespread pneumonia with transient clinical disease(2,3) that recapitulates mild-to-moderate human MERS-CoV cases(4,5). The combination of interferon-α2b and ribavirin was effective in reducing MERS-CoV replication in vitro(6); therefore, this strategy was initiated 8 h post-infection in the rhesus macaque model. Treated animals did not develop breathing abnormalities and showed no-to-very mild radiographic evidence of pneumonia. Moreover, treated animals showed reduced levels of systemic (serum) and local (lung) proinflammatory markers in addition to reduced viral genome copies, altered gene expression and less severe histopathological changes in the lungs. Taken together, these data suggest that treatment of MERS-CoV infected rhesus macaques with IFN-α2b and ribavirin reduces virus replication, moderates the host response and improves clinical outcome. As these two drugs are already used in combination in the clinic, IFN-α2b and ribavirin should be considered for management of MERS-CoV cases.
has issue date	2013-09-08(xsd:dateTime)
bibo:doi	10.1038/nm.3362
bibo:pmid	24013700
has license	no-cc
sha1sum (hex)	1d731161d1d09c1dee91dcd185d73734275b16df
schema:url	https://doi.org/10.1038/nm.3362
resource representing a document's title	Interferon-α2b and ribavirin treatment improves outcome in MERS-CoV-infected rhesus macaques
has PubMed Central identifier	PMC4093902
has PubMed identifier	24013700
schema:publication	Nat Med
resource representing a document's body	covid:1d731161d1d09c1dee91dcd185d73734275b16df#body_text
is schema:about of	named entity 'effective' named entity 'time' named entity 'gene' named entity 'developing' named entity 'disease' named entity 'rhesus macaque' named entity 'infections' named entity 'Middle East respiratory syndrome' named entity 'HISTOPATHOLOGICAL' named entity 'TRANSIENT' named entity '2C5' named entity 'INFECTED' named entity 'GLOBAL' named entity 'ADDITION' named entity 'DISEASE' named entity 'EVIDENCE OF' named entity 'EFFECTIVE' named entity 'ribavirin' named entity 'MERS-CoV' named entity 'interferon-α2b' named entity 'levels' named entity 'infection' named entity 'lung' named entity 'model organism' named entity 'The' named entity 'abnormalities' named entity 'develop' named entity 'reducing' named entity 'rhesus macaques' named entity 'ribavirin' named entity 'model organism' named entity 'host response' named entity 'proinflammatory' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'ribavirin' named entity 'rhesus macaques' named entity 'Ventana Medical Systems' named entity 'ribavirin' named entity 'host response' named entity 'helicase' named entity '2-mercaptoethanol' named entity 'Infection' named entity 'necropsy' named entity 'white blood cell counts' named entity 'gross pathology' named entity 'lungs' named entity 'microarray' named entity 'Agilent' named entity 'clinical signs' named entity 'Ingenuity Systems' named entity 'blood collection' named entity 'IFN' named entity 'antibody' named entity 'upregulation' named entity 'hematology' named entity 'viral genome' named entity 'acute respiratory distress syndrome' named entity 'lung' named entity 'severe acute respiratory syndrome' named entity 'middle lobe' named entity 'piloerection' named entity 'infection' named entity 'rhesus macaques' named entity 'ribavirin' named entity 'serum' named entity 'MERS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software